Answers are grounded in this paper and cite their sources.
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.
No takes yet. Share an insight, caveat, or question.
Bhattacharya et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: